Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial
Authors
Keywords
-
Journal
ONCOLOGY
Volume 83, Issue 1, Pages 1-9
Publisher
S. Karger AG
Online
2012-06-08
DOI
10.1159/000339152
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
- (2017) Eric T. Wong et al. Journal of the National Comprehensive Cancer Network
- Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
- (2011) Silvia Hofer et al. ACTA ONCOLOGICA
- Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
- (2011) R. Stupp et al. ANNALS OF ONCOLOGY
- Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial
- (2011) B Melichar et al. BRITISH JOURNAL OF CANCER
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells
- (2011) Carla Rohrer Bley et al. LUNG CANCER
- The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells
- (2011) Christoph Oehler et al. NEURO-ONCOLOGY
- Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
- (2011) J. L. Clarke et al. NEURO-ONCOLOGY
- Recurrent High-Grade Glioma
- (2010) Eudocia C. Quant et al. Current Treatment Options in Neurology
- Patupilone in cancer treatment
- (2010) Branislav Bystricky et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
- (2010) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Role of the Microenvironment for Radiosensitization by Patupilone
- (2009) C. R. Bley et al. CLINICAL CANCER RESEARCH
- Phase I Trial Using Patupilone (Epothilone B) and Concurrent Radiotherapy for Central Nervous System Malignancies
- (2009) Shannon Fogh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Metronomic Dosing Enhances the Anti-Angiogenic Effect of Epothilone B
- (2009) Mark W. Stalder et al. JOURNAL OF SURGICAL RESEARCH
- Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo
- (2008) Terence O’Reilly et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started